Abstract
The so-called exotic pulmonary mycoses are imported diseases in France. They are infrequent or exceptional and for this reason can be underdiagnosed or recognized with delay. Nevertheless, they are easily treatable infections with available antifungal agents. As a rule, the site of primary infection is the lung with ensuing clearance or chronic local infection and/or dissemination. Immunocompromised hosts are more prone to develop severe forms or reactivation of the disease.
MeSH terms
-
AIDS-Related Opportunistic Infections / diagnosis
-
AIDS-Related Opportunistic Infections / therapy
-
Amphotericin B / therapeutic use
-
Anti-Infective Agents / therapeutic use
-
Antifungal Agents / therapeutic use
-
Blastomycosis* / diagnosis
-
Blastomycosis* / therapy
-
Coccidioidomycosis* / diagnosis
-
Coccidioidomycosis* / therapy
-
Diagnosis, Differential
-
Histoplasmosis* / diagnosis
-
Histoplasmosis* / therapy
-
Humans
-
Itraconazole / therapeutic use
-
Ketoconazole / therapeutic use
-
Lung Diseases, Fungal* / diagnosis
-
Lung Diseases, Fungal* / therapy
-
Paracoccidioidomycosis* / diagnosis
-
Paracoccidioidomycosis* / therapy
-
Penicillium*
-
Sporotrichosis* / diagnosis
-
Sporotrichosis* / therapy
-
Sulfadiazine / therapeutic use
-
Travel
-
Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
Substances
-
Anti-Infective Agents
-
Antifungal Agents
-
Sulfadiazine
-
Itraconazole
-
Amphotericin B
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Ketoconazole